Maze Therapeutics, Inc.
MAZE Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$31.01
KIRA · Stoqly’s AI analyst, in plain words
- Maze Therapeutics, Inc. lost $131M in fiscal 2025.
- Free cash flow was −$113M in fiscal 2025, — of revenue.
Market cap
$1.8B
P/E
—
Revenue
—
Net income
−$131M
Free cash flow
−$113M
Operating margin
—
Maze Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$131M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Maze Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- Maze Therapeutics, Inc.
- CIK
- 0001842295
Maze Therapeutics, Inc. · MAZE
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Revenue | $168M | — |
| Operating margin | 34.4% | — |
| Net income | $52.2M | −$131M |
| Net margin | 31.2% | — |
| Diluted EPS | $1.25 | −$3.05 |
| Cash | ||
| Cash from operations | $76.0M | −$112M |
| Capital expenditure | $1.1M | $0.8M |
| Free cash flow | $74.8M | −$113M |
| FCF margin | 44.7% | — |
| Share count change | — | 1,474.0% |
| Debt and strength | ||
| Cash and short-term investments | $197M | $342M |
| Shareholders' equity | −$311M | $355M |
| Current ratio | 9.8x | 15.5x |
| Returns and quality | ||
| Return on equity | — | −599.0% |
| Return on tangible equity | — | −36.9% |
| Altman Z'' | −5.8 | 7.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$23.7M
6 insiders
Of sales under plans
90%
$21.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Maze Therapeutics, Inc. · MAZE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $31.01 a share, the company is worth $1.8B.
Source: SEC EDGAR XBRL filings (CIK 0001842295). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.